Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus
Abstract Aims Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of the fibrinolytic system and is mainly secreted from adipose tissue. It is associated with cardiovascular disease and has also been considered a possible early risk marker for type 2 diabetes. Here, we present the result...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-025-01629-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849724140838191104 |
|---|---|
| author | Jenny Hernestål-Boman Tina Öhman Jan-Håkan Jansson Marcus M. Lind Olov Rolandsson Ingvar A. Bergdahl Lars Johansson |
| author_facet | Jenny Hernestål-Boman Tina Öhman Jan-Håkan Jansson Marcus M. Lind Olov Rolandsson Ingvar A. Bergdahl Lars Johansson |
| author_sort | Jenny Hernestål-Boman |
| collection | DOAJ |
| description | Abstract Aims Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of the fibrinolytic system and is mainly secreted from adipose tissue. It is associated with cardiovascular disease and has also been considered a possible early risk marker for type 2 diabetes. Here, we present the results of a large prospective study investigating PAI-1 levels in relation to incident type 2 diabetes mellitus. Methods We conducted a prospective incident case-referent study within the Västerbotten Intervention Programme (VIP). Data on cardiovascular risk factors, fasting plasma glucose (FPG) and 2-hour plasma glucose (2-hPG) were collected at baseline health examination 1990–2005. Blood samples were collected and stored for future analyses. Participants were followed and 484 cases developed type 2 diabetes. Referents without type 2 diabetes were matched for sex, age, and year of participation, n = 484. Baseline plasma samples were analysed for PAI-1. Subgroup analysis was performed for 201 cases and 201 matched referents with normal baseline glucose levels (FPG < 6.1 and 2hPG < 8.9 mmol/L). Results Elevated baseline levels of PAI-1 were associated with incident type 2 diabetes after adjustments for BMI, family history of diabetes, smoking status, hypertension, FPG and 2hPG (PAI-1; OR = 1.87, 95% CI: 1.06–3.29). A similar result was shown in the subgroup analysis with 201 participants who had normal glucose levels at time of the health examination (PAI-1; OR = 2.68, 95% CI: 1.03–6.95). Conclusions Elevated PAI-1 levels in non-diabetic persons precede the manifestation of type 2 diabetes and can be detected before an elevation of FPG or 2-hPG is observed. |
| format | Article |
| id | doaj-art-235d1dbafb5e4f55a21036b33119e85c |
| institution | DOAJ |
| issn | 1758-5996 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj-art-235d1dbafb5e4f55a21036b33119e85c2025-08-20T03:10:50ZengBMCDiabetology & Metabolic Syndrome1758-59962025-02-011711610.1186/s13098-025-01629-4Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitusJenny Hernestål-Boman0Tina Öhman1Jan-Håkan Jansson2Marcus M. Lind3Olov Rolandsson4Ingvar A. Bergdahl5Lars Johansson6Department of Laboratory Medicine, University Hospital of UmeåDepartment of Public Health and Clinical Medicine, Umeå UniversityDepartment of Public Health and Clinical Medicine, Umeå UniversityDepartment of Public Health and Clinical Medicine, Umeå UniversityDepartment of Public Health and Clinical Medicine, Umeå UniversityDepartment of Public Health and Clinical Medicine, Umeå UniversityDepartment of Public Health and Clinical Medicine, Umeå UniversityAbstract Aims Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of the fibrinolytic system and is mainly secreted from adipose tissue. It is associated with cardiovascular disease and has also been considered a possible early risk marker for type 2 diabetes. Here, we present the results of a large prospective study investigating PAI-1 levels in relation to incident type 2 diabetes mellitus. Methods We conducted a prospective incident case-referent study within the Västerbotten Intervention Programme (VIP). Data on cardiovascular risk factors, fasting plasma glucose (FPG) and 2-hour plasma glucose (2-hPG) were collected at baseline health examination 1990–2005. Blood samples were collected and stored for future analyses. Participants were followed and 484 cases developed type 2 diabetes. Referents without type 2 diabetes were matched for sex, age, and year of participation, n = 484. Baseline plasma samples were analysed for PAI-1. Subgroup analysis was performed for 201 cases and 201 matched referents with normal baseline glucose levels (FPG < 6.1 and 2hPG < 8.9 mmol/L). Results Elevated baseline levels of PAI-1 were associated with incident type 2 diabetes after adjustments for BMI, family history of diabetes, smoking status, hypertension, FPG and 2hPG (PAI-1; OR = 1.87, 95% CI: 1.06–3.29). A similar result was shown in the subgroup analysis with 201 participants who had normal glucose levels at time of the health examination (PAI-1; OR = 2.68, 95% CI: 1.03–6.95). Conclusions Elevated PAI-1 levels in non-diabetic persons precede the manifestation of type 2 diabetes and can be detected before an elevation of FPG or 2-hPG is observed.https://doi.org/10.1186/s13098-025-01629-4Type 2 diabetesPlasminogen activator inhibitor-1Population studyVästerbotten intervention programme |
| spellingShingle | Jenny Hernestål-Boman Tina Öhman Jan-Håkan Jansson Marcus M. Lind Olov Rolandsson Ingvar A. Bergdahl Lars Johansson Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus Diabetology & Metabolic Syndrome Type 2 diabetes Plasminogen activator inhibitor-1 Population study Västerbotten intervention programme |
| title | Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus |
| title_full | Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus |
| title_fullStr | Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus |
| title_full_unstemmed | Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus |
| title_short | Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus |
| title_sort | elevated levels of pai 1 precede the occurrence of type 2 diabetes mellitus |
| topic | Type 2 diabetes Plasminogen activator inhibitor-1 Population study Västerbotten intervention programme |
| url | https://doi.org/10.1186/s13098-025-01629-4 |
| work_keys_str_mv | AT jennyhernestalboman elevatedlevelsofpai1precedetheoccurrenceoftype2diabetesmellitus AT tinaohman elevatedlevelsofpai1precedetheoccurrenceoftype2diabetesmellitus AT janhakanjansson elevatedlevelsofpai1precedetheoccurrenceoftype2diabetesmellitus AT marcusmlind elevatedlevelsofpai1precedetheoccurrenceoftype2diabetesmellitus AT olovrolandsson elevatedlevelsofpai1precedetheoccurrenceoftype2diabetesmellitus AT ingvarabergdahl elevatedlevelsofpai1precedetheoccurrenceoftype2diabetesmellitus AT larsjohansson elevatedlevelsofpai1precedetheoccurrenceoftype2diabetesmellitus |